Pfizer Tops Quarterly Estimates, Lowers Covid Revenue Guidance to $4 Billion
Macro·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Pfizer reported stronger-than-expected quarterly earnings, prompting an increase in the low end of its revenue guidance. The company has adjusted its full-year revenue expectation for Covid products to $4 billion, down from around $5 billion previously.
This revision reflects the ongoing shift in focus towards non-Covid products, which have shown significant strength in the current market environment.
Pfizer
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.”
CNBC — Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products